Empowering targeted therapy: lessons from rituximab

Science's STKE : Signal Transduction Knowledge Environment
Adam J Olszewski, Michael L Grossbard

Abstract

Rituximab, a monoclonal antibody directed against the B cell-specific protein CD20, has revolutionized lymphoma treatment by providing a highly effective form of therapy with relatively mild toxic side effects. Effective as a single agent against some forms of B cell lymphoma, rituximab also has a chemosensitizing effect, enhancing the efficacy of chemotherapy against other forms of the disease. Although the mechanisms whereby rituximab achieves its effects remain incompletely understood, these seem to involve at least three distinct phenomena: (i) antibody-dependent cell-mediated cytotoxicity, (ii) complement-mediated cell lysis, and (iii) stimulation of apoptosis in target cells. The latter occurs through interaction of complexes of rituximab and CD20 in lipid rafts, with elements of a signaling pathway involving Src kinases. Effector molecules trigger various gene expression events, leading to sensitization of malignant cells to proapoptotic stimuli. Lessons learned from the research on rituximab may be applied to the rational development of antibody-based therapies against other forms of cancer.

References

Mar 4, 1982·The New England Journal of Medicine·R A MillerR Levy
Sep 1, 1994·Immunology Today·T F Tedder, P Engel
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R G Anderson
Feb 7, 1998·The Journal of Biological Chemistry·J P DeansJ A Savage
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Sep 17, 1998·Japanese Journal of Cancer Research : Gann·H TajiY Morishima
Feb 5, 1999·European Journal of Immunology·C LéveilléW Mourad
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC A White
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanC Varns
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 7, 2001·Cancer Immunology, Immunotherapy : CII·D ShanO W Press
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM J Keating
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 15, 2002·Cancer Immunology, Immunotherapy : CII·Pina M CardarelliGeoffrey Yarranton
Feb 16, 2002·European Journal of Biochemistry·Laura D Zajchowski, Stephen M Robbins
Sep 5, 2002·European Journal of Immunology·Claire LévéilleReem Al-Daccak
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Jan 23, 2003·Cancer Biotherapy & Radiopharmaceuticals·Christos EmmanouilidesBenjamin Bonavida
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rajat BannerjiJohn C Byrd
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicola Di GaetanoJosée Golay
Aug 16, 2003·The Journal of Biological Chemistry·Haidong LiJulie P Deans
Aug 26, 2003·European Journal of Immunology·Jennifer AnolikFay Young
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam D KennedyRonald P Taylor
Mar 11, 2004·Blood Reviews·Blanche H Mavromatis, Bruce D Cheson
Apr 23, 2004·Current Opinion in Rheumatology·R John LooneyInãki Sanz

❮ Previous
Next ❯

Citations

Sep 25, 2009·European Journal of Nuclear Medicine and Molecular Imaging·G MalviyaA Signore
Jul 21, 2005·Cancer Immunology, Immunotherapy : CII·Bernd SchlerethPatrick A Baeuerle
Feb 2, 2008·Clinical Reviews in Allergy & Immunology·A KesselE Toubi
Apr 6, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Gaurav MalviyaAlberto Signore
Apr 20, 2013·Journal of Immunological Methods·Lionel LoubakiRenée Bazin
Oct 7, 2014·Indian Journal of Dermatology·Virendra N SehgalAnanta Khurana
Feb 22, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Nihal E AbdullaAvi B Markowitz
Jul 16, 2011·Molecular Immunology·Nina A DahaLeendert A Trouw
Jun 1, 2010·Dermatologic Clinics·David R Carr, Michael P Heffernan
Aug 8, 2007·Critical Reviews in Oncology/hematology·Zeping Zhou, Renchi Yang
Nov 5, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Thomas HaudebourgBernard Vanhove
Jan 20, 2006·Pediatric Blood & Cancer·Marcia M BieberNelson N H Teng
Dec 28, 2006·Journal of the American Academy of Dermatology·Julia E GravesMichael P Heffernan
Nov 1, 2007·Dermatologic Therapy·David R Carr, Michael P Heffernan
Jan 24, 2007·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Rafat A SiddiquiWilliam Stillwell

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.